Study to check theefficacy and safety of the oral Tofacitinib against methylprednisolone oral minipulsetherapy in vitiligo patients.
Phase 4
- Conditions
- Health Condition 1: L80- Vitiligo
- Registration Number
- CTRI/2024/02/062419
- Lead Sponsor
- Dr Imran Majid
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with a confirmed diagnosis of vitiligo, Washout period for Systemic medication for vitiligo for atleast 1 month before
enrolment, Written informed consent signed by the patient or legally acceptable
representative(s) in line with applicable regulation of country, Planned treatment in line with the Summary of Product Characteristics
Exclusion Criteria
any contraindication to any of the oral medications, women of childbearing age, pregnancy, lactation, any family history of diabetes in parents/siblings, Confirmed case of Latent Tuberculosis on investigation, unwillingness to conform to study protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The study is being planned to conduct a comparative assessment to explore the <br/ ><br>safety & efficacy of Oral Tofacitinib versus methylprednisolone oral minpulse <br/ ><br>therapy in vitiligo patients to develop/upgrade the literatureTimepoint: 1 year
- Secondary Outcome Measures
Name Time Method To obtain safety information in terms of adverse events on the use Oral Tofacitinib <br/ ><br>versus methylprednisolone oral minpulse therapy in vitiligo patients.Timepoint: 1 year